These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2396945)

  • 41. Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women.
    Worsley R; Robinson PJ; Bell RJ; Moufarege A; Davis SR
    Menopause; 2013 Jun; 20(6):640-5. PubMed ID: 23531683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased plasma HDL-cholesterol and apo A-I in breast cancer patients undergoing adjuvant tamoxifen therapy.
    Mastroianni A; Bellati C; Facchetti G; Oldani S; Franzini C; Berrino F
    Clin Biochem; 2000 Aug; 33(6):513-6. PubMed ID: 11074246
    [No Abstract]   [Full Text] [Related]  

  • 43. Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar rats.
    Vinitha R; Thangaraju M; Sachdanandam P
    Mol Cell Biochem; 1997 Mar; 168(1-2):13-9. PubMed ID: 9062889
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Apolipoprotein E4 allele influences the response of plasma triglyceride levels to tamoxifen in breast cancer patients.
    Chang NW; Chen FN; Wu CT; Lin CF; Chen DR
    Clin Chim Acta; 2009 Mar; 401(1-2):144-7. PubMed ID: 19103187
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
    Love RR; Hutson PR; Havighurst TC; Cleary JF
    Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of tamoxifen therapy on plasma lipid profile in patients of breast cancer.
    Gupta S; Tandon VR; Kapoor B; Gupta A; Gupta GD; Khajuria V
    J Assoc Physicians India; 2006 Mar; 54():183-6. PubMed ID: 16800341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property.
    Elisaf M; Bairaktari E; Nicolaides C; Fountzilas G; Tzallas C; Siamopoulos K; Tsolas O; Pavlidis N
    Anticancer Res; 1996; 16(5A):2725-8. PubMed ID: 8917378
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of tamoxifen on oestrogen binding, lipid and lipoprotein concentrations and blood clotting parameters in premenopausal women with breast pain.
    Caleffi M; Fentiman IS; Clark GM; Wang DY; Needham J; Clark K; La Ville A; Lewis B
    J Endocrinol; 1988 Nov; 119(2):335-9. PubMed ID: 3199064
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tamoxifen therapy and hepatic steatosis.
    Coskun U; Törüner FB; Günel N
    Neoplasma; 2002; 49(1):61-4. PubMed ID: 12044063
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment.
    Markopoulos C; Chrissochou M; Antonopoulou Z; Xepapadakis G; Papadiamantis J; Tzoracoleftherakis E; Gogas H
    Oncology; 2006; 70(4):301-5. PubMed ID: 17047401
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
    Ntukidem NI; Nguyen AT; Stearns V; Rehman M; Schott A; Skaar T; Jin Y; Blanche P; Li L; Lemler S; Hayden J; Krauss RM; Desta Z; Flockhart DA; Hayes DF;
    Clin Pharmacol Ther; 2008 May; 83(5):702-10. PubMed ID: 17713466
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of cytotoxic chemotherapy on serum lipid levels in breast cancer patients.
    Rzymowska J
    Pathobiology; 1999; 67(3):129-32. PubMed ID: 10394133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tamoxifen and partial oestrogen agonism in postmenopausal women.
    Miodrag A; Ekelund P; Burton R; Castleden CM
    Age Ageing; 1991 Jan; 20(1):52-4. PubMed ID: 1903020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men.
    Haffner SM; Mykkänen L; Valdez RA; Katz MS
    J Clin Endocrinol Metab; 1993 Dec; 77(6):1610-5. PubMed ID: 8263149
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels.
    Bertelli G; Pronzato P; Amoroso D; Cusimano MP; Conte PF; Montagna G; Bertolini S; Rosso R
    Breast Cancer Res Treat; 1988 Dec; 12(3):307-10. PubMed ID: 3228593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.
    Love RR; Wiebe DA; Feyzi JM; Newcomb PA; Chappell RJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1534-9. PubMed ID: 7932809
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent.
    Jordan VC; Fritz NF; Langan-Fahey S; Thompson M; Tormey DC
    J Natl Cancer Inst; 1991 Oct; 83(20):1488-91. PubMed ID: 1920495
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The relationship of total and free estrogens and sex hormone-binding globulin with lipoproteins in women.
    Longcope C; Herbert PN; McKinlay SM; Goldfield SR
    J Clin Endocrinol Metab; 1990 Jul; 71(1):67-72. PubMed ID: 2115047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
    Ellmén J; Hakulinen P; Partanen A; Hayes DF
    Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chemoprevention of breast cancer.
    Powles TJ; Hardy JR; Ashley SE; Cosgrove D; Davey JB; Dowsett M; McKinna A; Nash AG; Rundle SK; Sinnett HD
    Breast Cancer Res Treat; 1989 Oct; 14(1):23-31. PubMed ID: 2690969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.